CD4 and Kaposi's sarcoma: In contrast with non-users, no change in the HR for KS was seen among HAART users with CD4 cell counts in the range of 50–⩾350 cells μl−1 and the only significant risk increase was found for CD4 cell count less than 50 cells μl−1 at enrolment (HR, 3.26; 95% CI, 1.53–6.91).